<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268618</url>
  </required_header>
  <id_info>
    <org_study_id>10-SUS-05-NAT-01</org_study_id>
    <nct_id>NCT01268618</nct_id>
  </id_info>
  <brief_title>Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Dual-center Study on the Effect of Healthy Trinity (Retail Label)/Trenev Trio (Professional Label) on Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sprim Advanced Life Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sprim Advanced Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      • To confirm the efficacy of the probiotic product Healthy Trinity (retail label)/Trenev Trio
      (professional label) in the improvement of symptoms in adult patients with
      diarrhea-predominant irritable bowel syndrome (IBS-D) and functional dyspepsia

      Secondary Objective:

      • To confirm the safety of the probiotic product Healthy Trinity (retail label)/Trenev Trio
      (professional label) in adult patients with IBS-D and functional dyspepsia
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal pain severity</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool consistency (Bristol Stool Chart)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyspepsia Symptom Severity Index (DSSI)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with 1 or more adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>IBS-D and Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:
Lactobacillus acidophilus NAS, 30 billion CFU
Bifidobacterium bifidum Malyoth, 120 billion CFU
Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules, 3x/day placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 75 years

          2. Diagnosed with IBS-D including: a) weekly average of worst abdominal pain in the last
             24 hours of ≥3 on a 0-10 scale, and b) weekly average of Bristol Stool form of ≥6 on a
             1-7 scale

          3. Diagnosed with functional dyspepsia defined as presence of at least one of the
             following symptoms: bothersome postprandial fullness, early satiation, epigastric
             pain, or epigastric burning AND no evidence of structural disease that is likely to
             explain the symptoms

          4. History of IBS-D and dyspepsia symptoms for at least 12 weeks

          5. Agree to use contraception throughout study period, unless postmenopausal or
             surgically sterile (females only)

          6. Able to understand the nature and purpose of the study including potential risks and
             side effects

          7. Willing to consent to study participation and to comply with study requirements

          8. Successful completion of 2-week placebo-only run-in period, defined as ≥90% product
             compliance and completion of required questionnaires

        Exclusion Criteria:

          1. Major gastrointestinal complication, e.g. Crohn's disease or ulcer

          2. Prior abdominal surgery with the exception of hernia repair and appendectomy

          3. Subjects over 60 years who have not had a sigmoidoscopy or colonoscopy in the past 10
             years

          4. Clinically significant systemic disease

          5. Life expectancy &lt; 6 months

          6. Pregnant female or breastfeeding

          7. Lactose intolerance

          8. Immunodeficient subjects

          9. Anti-psychotic medication within the prior 3 months or major psychiatric disorder
             within the past 2 years

         10. Systemic steroids within the prior month

         11. Current treatment with nasogastric tube, ostomy, or parenteral nutrition

         12. Use of proton pump inhibitors

         13. Eating disorder

         14. Recent (&lt; 2 weeks) antibiotic administration

         15. History of alcohol, drug, or medication abuse

         16. Daily consumption of probiotics, fermented milk, and/or yogurt

         17. Known allergies to any substance in the study product

         18. Participation in another study with any investigational product within 3 months of
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duane Wombolt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Associates of Tidewater</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Wyatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>In-Quest Medical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>In-Quest Medical Research, LLC</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2010</study_first_submitted>
  <study_first_submitted_qc>December 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2010</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Larry Miller, PhD</name_title>
    <organization>Sprim Advanced Life Sciences</organization>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

